In this article, we will discuss: Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. For more stocks, you can head to Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks: Top 5 Stocks.

In an appearance on CNBC’s Fast Money in January, Ray Stevens, CEO of Structure Therapeutics, discussed the unmet potential in the obesity market. The weight loss drug sector has stood side-by-side with AI when it comes to investor attention. Share price movement in the stock of the top player, Eli Lilly, led the firm to become the first trillion-dollar pharmaceutical company last year.

With data from banking giant JPMorgan suggesting that 25 million Americans will be on GLP-1 treatment by 2030, Stevens believes that not only is obesity a pandemic, but he’s relieved that it’s “finally getting recognized as a pandemic.” In his discussion, he quoted estimates that suggest that by 2030, more than three billion people will be obese globally. Within the US, he outlined that “we’re talking about more than a hundred million people in the United States alone.” Using this statistic to outline that since “right now, today, they’re only being served around being served around five million people based on script data.” there was “a real big unmet need to address this unmet pandemic, and as mentioned, all the adjacent diseases that come around with excess weight.”

Our Methodology

To make our list of Jim Cramer’s hottest GLP-1 and weight stock picks, we made a list of weight loss and GLP-1 stocks and those that serve the industry, he was optimistic about in 2025. Then, their performance since the comments were made was calculated, and the stocks were ranked accordingly. Additionally, the number of hedge fund investors back then was also mentioned. Finally, the number of investors as of the fourth quarter of 2025 was also mentioned for additional context.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10. Viking Therapeutics Inc. (NASDAQ:VKTX)

Number of Hedge Fund Holdings in Q3 2024: 41

Number of Hedge Fund Holdings in Q4 2025: 38

Performance Since Cramer’s Remarks: -0.7%

Date/Month of Cramer’s Remarks: January 28th, 2025

Viking Therapeutics Inc. (NASDAQ:VKTX) is a biotechnology company developing treatments that focus on metabolic ailments. The firm is currently developing a weight loss drug under the title VK-2735 that is designed to work on GLP-1 and GIP receptors. Viking Therapeutics Inc. (NASDAQ:VKTX)’s shares are up by 34% over the past year and are slightly down since Cramer discussed the firm in January 28 on Mad Money. One major reason behind the lackluster performance is a massive drop in August 2025 when Viking Therapeutics Inc. (NASDAQ:VKTX)’s stock closed 42% lower on the 19th. On that day, the firm released results of its mid-stage trial of the drug. The trial saw participants lose 12% of their body weight, while, according to media reports, investors were aiming for higher percentages. Viking Therapeutics Inc. (NASDAQ:VKTX)’s VK-2735 is a weight loss pill, and in late 2025, Novo Nordisk became the first to launch such a product. The performance also vindicated Cramer, as he had remarked:

“Okay, people, people think that even if Lily’s stock can’t go up, why would we want Viking Therapeutics? And a lot of people were in it for a takeover. So far it doesn’t look like that’s materializing, so they’re giving up and they are selling it. I prefer Eli Lilly.”

9. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holdings in Q4 2024: 68

Number of Hedge Fund Holdings in Q4 2025: 75

Performance Since Cramer’s Remarks: 10.6%

Date/Month of Cramer’s Remarks: March 11th, 2025 

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that focuses on a variety of ailments involving the neurological, cardiovascular, and other ailments. The firm is focused on developing weight loss drugs that enable users to retain lean muscle mass while shedding weight. Over the year, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s shares are up by 16.32%, and since Cramer discussed the firm in March 2025, they are up by 10.6%. The stock closed 11.8% higher on October 28th as the firm reported its third-quarter earnings report. The results saw the firm post $3.75 billion in revenue and $11.83 in quarterly profit per share to beat analyst estimates of $3.59 billion and $9.59. Year-to-date, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s shares are down by 4.9%. A notable dip came in January when the shares dipped significantly between the 9th and 16th. Bank of America discussed the firm in January as it bumped Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s rating to Buy from Underperform and increased the share price target to $860 from $627. Here’s what Cramer had said about the firm in March 2025 on Mad Money:

“I will tell you this, Regeneron, I want you to own it. I think it’s doing better than people realize. That is a good stock.”